NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · USD

BriaCell Therapeutics Corp. (BCTXL) Stock Analysis

BriaCell Therapeutics Corp. (BCTXL) is a stock listed on NASDAQ and quoted in US Dollar.

BCTXL

$0.95

+$0.01 (+0.71%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCTXL with… →

BCTXL Key Statistics

As of Sep 4, 2026
Trading
Open
$1.00
Previous Close
$0.94
Day's Range
0.87–0.99
52-Week Range
0.87–0.99
Volume
28.14K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.52
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Analysis

Data-derived

Company Overview

BriaCell Therapeutics Corp. trades under the ticker BCTXL.

BCTXL last closed at $0.95 on September 4, 2026. That is +$0.01 (+0.71%) against the previous close. The 52-week range on file runs from $0.87 to $0.99. The latest close sits 8.8% above that 52-week low.

Financial Health

The reported profit margin is 0%.

Valuation Assessment

The stored price history starts on January 30, 2026, and the total return since then is −17.69%. The reported beta is 1.52.

Growth & Income

The record shows no dividend for BCTXL.

2026 is still running; the price is −17.69% year to date.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Visit website →